The FDA on April 18, 2024, approved ALECENSA® for adjuvant treatment following tumor resection in patients with Anaplastic Lymphoma Kinase (ALK)-positive Non-Small Cell Lung Cancer (NSCLC), as detected by an FDA-approved test. ALECENSA® is a product of Genentech, Inc.
Bottom Ad
Advertisement
Subscribe
